Sichuan pharmaceutical companies are showing off!

Recently, the good news of Better Pharmaceutical’s product line has continued: Cefmetazole Sodium for Injection was the first to have been evaluated, the first class new drug BT-101094 capsule was approved for clinical use, and it has reached a cooperation with Guangzhou Kangchen in the field of contrast agents

The first review of a large variety of 1.

According to data from Meinenet, in 2020, the sales of terminal cefmetazole injections in public medical institutions in China will exceed 1.

In 2020, the sales of terminal cefazolin injections in China's public medical institutions exceeded 3 billion yuan, and Shenzhen China Resources Jiuxin Pharmaceuticals accounted for 66% of the market share

Up to now, Better Pharmaceuticals (including subsidiaries, the same below) has 39 varieties (59 product specifications) passed/deemed to have passed the consistency evaluation

Better Pharmaceuticals passed/deemed passed the consistency evaluation varieties

Data source: Meinenet MED2.

In the five batches and six rounds of centralized procurement carried out by the country, Better Pharmaceuticals has won the bid for its products, and a total of 19 varieties have won the bid for centralized procurement

Selection of the National Centralized Procurement of Better Pharmaceuticals

Data source: Shanghai Sunshine Pharmaceutical Purchasing Network

Enter the 15 billion contrast agent market, grab the first imitation of 1 billion large varieties

Recently, Kangchen Pharmaceuticals issued an announcement stating that its subsidiary Guangzhou Kangchen and Better Pharmaceuticals have reached a cooperation in the field of contrast agents

Better Pharmaceuticals is a new entrant in the field of contrast agents, covering "raw materials + preparations"

In 2021, Better Pharmaceuticals reported to produce contrast media

According to data from Menet.

Sales of Terminal Contrast Agents in Public Medical Institutions in China (Unit: 100 million yuan)

Data source: Mi Nei.

Iodixanol injection has been included in the fifth batch of centralized procurement, and 4 companies including Yangzijiang Pharmaceutical Group, General Electric, Stellite, and Nanjing Zhengda Tianqing won the bid

10 new class 1 drugs are in force, 31 new products are coming

Better Pharmaceuticals focuses on researching Class 1 new drugs

Better Pharmaceuticals insists on independent innovation, and continues to lay out research pipelines in the fields of innovative drugs, improved new drugs, and high-end generic drugs, covering tumors and autoimmune diseases, anti-infection, respiratory system, cardiovascular and cerebrovascular, mental and nervous systems, etc.

The company has more than 150 research projects, covering 10 class 1 new drugs such as BT-1053 and BT-101, and 3 improved new drugs including remazolam hydrobromide for injection and dexmedetomidine hydrochloride nasal spray.

Among the first class of new drugs published by Better Pharmaceuticals, BT-1053 is a second-generation BTK small molecule inhibitor, intended for the treatment of B-cell lymphoma, and is currently in phase I clinical trials

Bite Pharmaceutical Co.
, Ltd.
is reviewing the consistency evaluation (including new classification) varieties

Data source: Meinenet MED2.
0 Chinese Drug Evaluation Database

According to data from Meinenet, there are currently 31 new registered classifications under review by Better Pharmaceuticals, which will be deemed to have passed the consistency evaluation after being approved for production
.
Among them, there are 9 and 7 anti-infective drugs for respiratory system and systemic use respectively
.
No first imitation (including the first imitation of the dosage form) has been approved for 9 varieties, and Better Pharmaceuticals will compete with a number of pharmaceutical companies for the first imitation
.

In terms of supplementary applications for consistency evaluation, 10 products of Better Pharmaceutical are under review and approval
.
Except for digoxin tablets, all other varieties are injections
.
Four varieties of dexamethasone sodium phosphate injection, digoxin tablets, amikacin sulfate injection, and ozagrel sodium for injection were first declared by Better Pharmaceuticals, and it is likely to become the first company to pass the review
.